<DOC>
	<DOC>NCT00788333</DOC>
	<brief_summary>This is a Phase I/II study to evaluate the safety profile, tolerability, pharmacokinetics and pharmacodynamics following daily oral doses of 50 to 200 mg of BMS-754807 in combination with trastuzumab (Herceptin®) in subjects with advanced or metastatic Her-2-positive breast cancer. In addition, the study is expected to identify the recommended dose or dose range of BMS-754807 in combination with trastuzumab for Phase II studies and provide preliminary evidence of anti-tumor activity in Her-2-positive breast cancer subjects after trastuzumab failure</brief_summary>
	<brief_title>Combination Study of BMS-754807 and Herceptin® in Patients With Advanced or Metastatic Her-2-positive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>For additional information on this trial, please call (910) 5582913 Subjects with locally advanced or metastatic Her2positive breast cancer who have failed at least one trastuzumab containing regimen. Prior treatment with other Her2targeted agents (e.g. lapatinib, pertuzumab, trastuzumab DM1 etc.) is allowed Histologic or cytologic diagnosis of Her2positive breast cancer ECOG status 0 1 Symptomatic brain metastasis Any condition requiring chronic use of steroids Any disorder with dysregulation of glucose homeostasis (history of Type 1 or 2 Diabetes Mellitus or prediabetic symptoms History of glucose intolerance Women of childbearing potential unwilling or unable to use acceptable contraception methods</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Advanced or Metastatic Her-2-positive Breast Cancer</keyword>
</DOC>